Clinical Trial Update: Subtherapeutic Dose of Piracetam as a Therapy Adherence Marker [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluating a subtherapeutic dose of piracetam as a therapy adherence marker.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Drug Adherence Marker

Drugs mentioned

• Piracetam (piracetam)

Snippet

Sponsor: The Netherlands Cancer Institute | Conditions: Drug Adherence Marker | Phase 4 | Status: UNKNOWN